Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-06-04

Clinical Trial Update: An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy, safety, and tolerability of Simeprevir (TMC435) in treatment-naive genotype 1 Hepatitis C patients; results were posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Simeprevir (simeprevir)

Snippet

Sponsor: Janssen R&D Ireland | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2014-06-04